Geneva, Switzerland, Friday, 25 June 2010: Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma (HCC) the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.
"This HCC conference is a significant milestone in the field of HCC research. We are encouraged by the range of topics and eminent researchers in attendance, bringing new understanding and celebrating new research opportunities from across the world that will help address the current challenges we face as clinicians. This ultimately will help drive our ultimate goal of reducing the suffering caused by this devastating and debilitating disease," commented Professor Josep M Llovet, chair of the HCC special conference and Professor of Research, Liver Unit, Hospital Clnic, Barcelona, Spain and Professor of Medicine, Director, Mount Sinai Liver Cancer Research Program, Mount Sinai School of Medicine, New York.
At the two-day conference, entitled: Hepatocellular Carcinoma from genomics to treatment, organised by the European Association for the Study of the Liver (EASL), experts will address a range of key topics, including: the genetic make-up of HCC, the molecular signatures and biomarkers and other advancements to determine diagnosis and prognosis of HCC, and potential disease targets to develop new treatment strategies. Specifically, several novel molecular targeted therapies are currently being tested in advanced stages of clinical research, and their results expected by 2011-14 might improve the standard of care of patients suffering this neoplasm.
HCC is a cancer originating in liver cells and is one of the most common types of tumour. Worldwide, HCC accounts for approximately 5.4% of all cancers3 and causes 610,000 deaths per year
|Contact: Isabelle Scali|
European Association for the Study of the Liver